Navigation Links
DSMB Again Supports Continuation of the Phase III Clinical Trial of Medidur(TM) FA for the Treatment of DME
Date:3/24/2008

ATLANTA, March 24 /PRNewswire/ -- After completing its review of safety and efficacy data currently available, an independent Data Safety Monitoring Board (DSMB) has once again recommended that the two pivotal Phase III clinical trials, known collectively as the FAME(TM) (Fluocinolone Acetonide in Diabetic Macular Edema) Study can continue under the current protocol, without change. The trial is studying the use of Medidur FA for the treatment of diabetic macular edema (DME).

FAME is two, duplicate, double-masked, randomized, multi-center studies that are following 956 patients in the U.S., Canada, Europe and India for 36 months in support of a planned global registration filing, with safety and efficacy assessed after two years of follow-up. Enrollment for the FAME study was completed in October 2007.

"Alimera is pleased with the response from the DSMB that they have once again recommended that our investigative efforts around this treatment continue without change to the current protocol," said Alimera CEO Dan Myers. As of this latest DSMB review, we continue to be on track for regulatory submissions in early 2010."

Earlier this month, Alimera announced that it would be assuming a majority stake in the development of Medidur FA. Alimera is also working with Emory University on an exploratory treatment using the Medidur delivery system with an NADPH oxidase inhibitor for the treatment of dry age-related macular degeneration (AMD).

Medidur, a tiny, injectable insert, is being studied as a way to deliver fluocinolone acetonide, a corticosteroid, to the retina for up to three years as a treatment for diabetic macular edema (DME). Using a proprietary 25 gauge injector system, an eye care professional injects the Medidur insert into the vitreous through a minimally invasive procedure in an outpatient setting.

Currently, 7.5 percent of the U.S. population has diabetes. Over time, almost all diabetics will develop some form of dia
'/>"/>

SOURCE Alimera Sciences Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Vical Begins Phase 1 Trial of DNA Vaccine Against H5N1 Pandemic Influenza
2. Oritavancin Demonstrates Superior In Vitro Activity to Vancomycin and Metronidazole Against C. Difficile Bacteria
3. Oritavancin Demonstrates Potent and Rapid In Vitro Activity Against MRSA, VRE and Other Strains of Resistant Bacteria
4. Molnlycke Drives Home the Fight Against Staph and Other MRSA Infections
5. Mayo Clinic Study Finds FDA Warning Against Anti-Nausea Drug Droperidol Unnecessary
6. Targeted Nanoparticles Offer Promise in the Battle Against Cancer
7. Interim Safety Data Favorable for Vicals Phase 2 Trial of DNA Vaccine Against CMV
8. Roche Announces Positive Results in Solid Tumors Using Human Monoclonal Antibody Against IGF-1R (R1507)
9. Jennerex Presents Clinical Data From JX-594 Demonstrating Tumor Efficacy Against Advanced Liver Cancers
10. Semafores PI3 Kinase Inhibitor SF1126 is Active Against Tumor and Tumor Cells and Synergizes with Standard Chemotherapy Agents
11. BD and PEPFAR Collaborate to Strengthen Laboratory Systems in Fight Against HIV/AIDS and TB
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... May 21, 2013 RenovoRx ( www.renovorx.com ) ... "Top Startup" Award at TiEcon 2013, the world,s largest ... team and quality of entrepreneurial ideas. RenovoRx was honored ... Santa Clara Convention Center. ... of the most enterprising startup companies across five verticals: ...
(Date:5/21/2013)... 2013 /PRNewswire-iReach/ -- The 2013 Pharma ChemOutsourcing Show slated ... greatest number of "Emerging" small molecule biotech company ... Alexay .  "No one saw this coming", ... show,s still 4 months away and we may end ... big surprise and great news for attendees". Thecurrent list ...
(Date:5/21/2013)... 21, 2013  IsoRay, Inc. (AMEX: ISR ... entered into an exclusive international distribution agreement with IASIS ... in Greece . IsoRay is a ... medical radioisotope applications for brain cancer, lung cancer, head ... IASIS Medical is ideally suited to ...
Breaking Medicine Technology:RenovoRx Named Winner of 2013 TiE50 "Top Startup" 2Emerging Pharma at ChemOutsourcing 2013 in Record Numbers for Upcoming September Show 2IsoRay Announces A New International Distributor For Greece 2IsoRay Announces A New International Distributor For Greece 3
... PALO ALTO, Calif.--(BUSINESS WIRE)--Apr 12, 2007 - ... from its Phase,2 clinical trial of Hematide(TM) ... week at the National Kidney Foundation (NKF),2007 ... trial in patients previously treated with,three-times weekly ...
... 2007--The costs of eradicating,poliomyelitis from the remaining infected ... lower than the long term costs of trying,to ... vaccine is almost three times more effective against,type ... are,the findings of two Articles published Online and ...
Cached Medicine Technology:Affymax Announces Results From Phase 2 Clinical Trial of Hematide,for the Treatment of Anemia in Dialysis Patients 2Affymax Announces Results From Phase 2 Clinical Trial of Hematide,for the Treatment of Anemia in Dialysis Patients 3Costs of Eradicating Poliomyelitis Now Are Much Lower Than Trying,to Control It Later 2Costs of Eradicating Poliomyelitis Now Are Much Lower Than Trying,to Control It Later 3
(Date:5/21/2013)... May 2013, Paris, France: The Orsiro stent, which ... a biodegradable polymer, demonstrated non-inferiority to the Xience ... of in-stent late lumen loss at nine months ... at EuroPCR 2013 today. , The BIOFLOW-II substudy ... (OCT) to quantitatively assess neointimal hyperplasia and stent ...
(Date:5/21/2013)... York, New York (PRWEB) May 21, 2013 ... Wright Conserve hip replacement lawsuits in ... an Order in response to a request from Plaintiffs’ ... of the Defendant. The May 17th Order grants ... interviews may be conducted. (In re: Wright Medical Technology, ...
(Date:5/21/2013)... Diversity Focus, a non-profit organization striving ... residents in the Creative Corridor region, is releasing results ... news conference on Thursday, May 23rd at 10:30 a.m. ... 2008. , The survey is a critical ... efforts that attract, nurture and retain people of diverse ...
(Date:5/21/2013)... Modern couples have countless strains on ... Sexuality and Relationship Workshops, couples are learning the ... habits for their relationship. There are both private ... individuals at Texas Counseling. Their goal is to ... to develop long term solutions. , Developing ...
(Date:5/21/2013)... AURORA, Colo. (May 21, 2013) Research into genetic ... the University of Colorado School of Medicine may lead ... to a paper published online by JAMA . ... helps predict survival in some cases of pulmonary fibrosis, ... three years. As a result of the study, researchers ...
Breaking Medicine News(10 mins):Health News:Biodegradable stent proves non-inferior to drug-eluting stent 2Health News:Wright Hip Lawsuit News: Bernstein Liebhard LLP Notes Issuance of New Order in Federal Wright Conserve Hip Replacement Litigation 2Health News:Wright Hip Lawsuit News: Bernstein Liebhard LLP Notes Issuance of New Order in Federal Wright Conserve Hip Replacement Litigation 3Health News:Diversity Focus Announces Results from 2013 Creative Corridor Survey at News Conference on Thursday, May 23rd at 10:30 a.m. 2Health News:Workshops Offered To Identify Underlying Challenges That Put Strain On Relationships 2Health News:Researchers find genetic tie to improved survival time for pulmonary fibrosis 2
... Nov. 21 Mayor Rick Baker and members of the ... Association of Florida Gulfcoast Area on its Faces of ... area residents about the importance of annual vaccination to help ... , , In support of ...
... outbreak in Uganda genetically distinct from other known species , , ... the deadly Ebola virus has been identified by American and ... ebolavirus , caused an outbreak in western Uganda in 2007. ... species, differing by more than 30 percent at the genetic ...
... 21 Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX ... received notice from The Nasdaq Stock Market ("Nasdaq") stating ... Marketplace Rule 4310(c)(3), which requires the Company to have ... market value of listed securities, or $500,000 of net ...
... Escalon Medical Corp. (Nasdaq: ESMC ) today ... private placement of common stock and common stock purchase warrants ... shares of common stock at $1.10 per share. The ... of common stock at an exercise price of $1.21 per ...
... Interoperability pioneer Compressus,Inc. today introduced the ... Systems Integration software solutions with the release ... new release features a full,integration with GE ... comprehensive interoperability solutions package that increase the,efficiency ...
... DIEGO, Nov. 21 Vical Incorporated,(Nasdaq: VICL ... of 29 employees, approximately 20% of the company,s total ... restructuring,the company will have approximately 120 employees and expects ... $4 million annually. , ...
Cached Medicine News:Health News:Mayor Rick Baker and the American Lung Association Encourage St. Petersburg Residents to Get Immunized Against Influenza 2Health News:Mayor Rick Baker and the American Lung Association Encourage St. Petersburg Residents to Get Immunized Against Influenza 3Health News:Keryx Biopharmaceuticals Receives Nasdaq Notification 2Health News:Keryx Biopharmaceuticals Receives Nasdaq Notification 3Health News:Escalon(R) Medical Corp. Completes $1.1 Million Private Equity Financing 2Health News:Escalon(R) Medical Corp. Completes $1.1 Million Private Equity Financing 3Health News:Compressus' Next Generation MEDxConnect(TM) Interoperability Solutions Feature GE Centricity and Philips iSite Integrations 2Health News:Compressus' Next Generation MEDxConnect(TM) Interoperability Solutions Feature GE Centricity and Philips iSite Integrations 3Health News:Compressus' Next Generation MEDxConnect(TM) Interoperability Solutions Feature GE Centricity and Philips iSite Integrations 4Health News:Vical Announces Strategic Restructuring and Staff Reduction 2Health News:Vical Announces Strategic Restructuring and Staff Reduction 3
... provide protection to the exposed airway of the ... making it ideal for active young children as ... heat and moisture recovery, it ensures patient comfort ... filters have ISO standard tapered ends to assure ...
... protection to the exposed airway of the tracheostomy ... it ideal for active young children as well ... and moisture recovery, it ensures patient comfort and ... have ISO standard tapered ends to assure a ...
For use with: , pulmonary function testing , nebulizer compressors , humidifiers , concentrators , proximal pressure lines ...
Indications For Usage: , ,For use during pulmonary lung function testing...
Medicine Products: